{"id":201522,"date":"2022-04-29T05:50:41","date_gmt":"2022-04-29T05:50:41","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=90922"},"modified":"2022-04-29T05:50:41","modified_gmt":"2022-04-29T05:50:41","slug":"resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022","status":"publish","type":"post","link":"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/","title":{"rendered":"ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022"},"content":{"rendered":"<div>\n<ul type=\"disc\">\n<li><em>Year-over-year revenue grows 12%, operating profit up 5%,\u00a0non-GAAP\u00a0operating profit up 5%<\/em><\/li>\n<\/ul>\n<p><em>Note: A webcast of ResMed\u2019s conference call will be available at 4:30 p.m. ET today at\u00a0<\/em><a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DgjwHH4Lp_BAp1TuFQnthe1n_M9907HBNAE2WmZZs7vC9NsVunt3SYQulgeKMuTmaFo0DMnVpesG6_gqQYXNU77V34SmYYKVxbJdnwMIOqtsfXfG71wwCHRcpYZsLxDIrvau_0hgLyN5o7CR4w4UcIw%3D%3D&amp;source=gmail-html&amp;ust=1651297750446000&amp;usg=AOvVaw0_R7jfOksc2p5ljxd4kPiq\"  rel=\"nofollow noreferrer\"><em><u>http:\/\/investor.resmed.com<\/u><\/em><\/a><\/p>\n<p>SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) &#8212; ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March\u00a031, 2022.<\/p>\n<p><strong>Third Quarter 2022 Highlights<\/strong><br \/>\n<em>All comparisons are to the prior year period<\/em><\/p>\n<ul type=\"disc\">\n<li>Revenue increased by 12% to $864.5 million; up 14% on a constant currency basis<\/li>\n<li>Gross margin contracted 140 bps to 56.8%;\u00a0non-GAAP\u00a0gross margin contracted 150 bps to 58.1%<\/li>\n<li>Income from operations increased 5%;\u00a0non-GAAP\u00a0operating profit up 5%<\/li>\n<li>Diluted earnings per share of $1.22;\u00a0non-GAAP\u00a0diluted earnings per share of $1.32<\/li>\n<\/ul>\n<p>\u201cOur third-quarter results reflect strong performance across our business, resulting in double-digit top-line revenue growth including extraordinary demand in our sleep and respiratory care business segment as well as solid high-single-digit growth in our software-as-a-service segment,\u201d said Mick Farrell, ResMed CEO. \u201cI am proud of our global team\u2019s ability to pivot and drive continued growth while ongoing supply chain disruptions and a competitor\u2019s recall continue to limit our ability to meet the incredible demand for our products. We remain focused on delivering products, software, and services for patients, working closely with our supply chain partners as well as physicians, providers, and beyond, to prioritize care for patients who most need it.<\/p>\n<p>\u201cWhile the current industry and macroeconomic environment remain uncertain, our long-term strategy allows us to keep our focus on helping 250 million lives in 2025. Our end-market demand from patients and providers remains strong, and our digital health technologies continue to deliver value. We are supporting patients with the world-leading portfolio of sleep apnea therapy, respiratory care therapy, and digital health solutions they need, as we deliver value for all of our customers.\u201d<\/p>\n<p><strong>Financial Results and Operating Metrics<\/strong><br \/>\n<em>Unaudited; $ in millions, except for per share amounts<\/em><\/p>\n<table>\n<tbody>\n<tr>\n<td><\/td>\n<td colspan=\"13\">Three Months Ended<\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td colspan=\"3\">March 31,<br \/>\n2022<\/td>\n<td><\/td>\n<td colspan=\"3\">March 31,<br \/>\n2021<\/td>\n<td><\/td>\n<td colspan=\"2\">%\u00a0Change<\/td>\n<td><\/td>\n<td colspan=\"2\">Constant<br \/>\nCurrency\u00a0<sup><em>(A)<\/em><\/sup><\/td>\n<\/tr>\n<tr>\n<td>Revenue<\/td>\n<td>$<\/td>\n<td>864.5<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>768.8<\/td>\n<td><\/td>\n<td><\/td>\n<td>12<\/td>\n<td>%<\/td>\n<td><\/td>\n<td>14<\/td>\n<td>%<\/td>\n<\/tr>\n<tr>\n<td>Gross margin\u00a0<sup><em>(B)<\/em><\/sup><\/td>\n<td><\/td>\n<td>56.8<\/td>\n<td>%<\/td>\n<td><\/td>\n<td><\/td>\n<td>58.2<\/td>\n<td>%<\/td>\n<td><\/td>\n<td>(2<\/td>\n<td>)<\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Non-GAAP\u00a0gross margin\u00a0<sup><em>(B)<\/em><\/sup><\/td>\n<td><\/td>\n<td>58.1<\/td>\n<td>%<\/td>\n<td><\/td>\n<td><\/td>\n<td>59.6<\/td>\n<td>%<\/td>\n<td><\/td>\n<td>(3<\/td>\n<td>)<\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Selling, general, and administrative expenses<\/td>\n<td><\/td>\n<td>182.4<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>160.4<\/td>\n<td><\/td>\n<td><\/td>\n<td>14<\/td>\n<td><\/td>\n<td><\/td>\n<td>17<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Research and development expenses<\/td>\n<td><\/td>\n<td>66.8<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>55.9<\/td>\n<td><\/td>\n<td><\/td>\n<td>19<\/td>\n<td><\/td>\n<td><\/td>\n<td>22<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Income from operations<\/td>\n<td><\/td>\n<td>234.3<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>223.4<\/td>\n<td><\/td>\n<td><\/td>\n<td>5<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Non-GAAP\u00a0income from operations\u00a0<sup><em>(B)<\/em><\/sup><\/td>\n<td><\/td>\n<td>253.0<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>241.8<\/td>\n<td><\/td>\n<td><\/td>\n<td>5<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Net income (loss)<\/td>\n<td><\/td>\n<td>179.0<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>(78.5<\/td>\n<td>)<\/td>\n<td><\/td>\n<td colspan=\"2\">NM<\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Non-GAAP\u00a0net income\u00a0<sup><em>(B)<\/em><\/sup><\/td>\n<td><\/td>\n<td>193.3<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>190.4<\/td>\n<td><\/td>\n<td><\/td>\n<td>2<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Diluted earnings (loss) per share<\/td>\n<td>$<\/td>\n<td>1.22<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>(0.54<\/td>\n<td>)<\/td>\n<td><\/td>\n<td colspan=\"2\">NM<\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Non-GAAP\u00a0diluted earnings per share\u00a0<sup><em>(B)<\/em><\/sup><\/td>\n<td>$<\/td>\n<td>1.32<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1.30<\/td>\n<td><\/td>\n<td><\/td>\n<td>2<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>NM\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Not meaningful<\/p>\n<table>\n<tbody>\n<tr>\n<td><\/td>\n<td colspan=\"13\">Nine Months Ended<\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td colspan=\"3\">March 31,<br \/>\n2022<\/td>\n<td><\/td>\n<td colspan=\"3\">March 31,<br \/>\n2021<\/td>\n<td><\/td>\n<td colspan=\"2\">% Change<\/td>\n<td><\/td>\n<td colspan=\"2\">Constant<br \/>\nCurrency\u00a0<sup><em>(A)<\/em><\/sup><\/td>\n<\/tr>\n<tr>\n<td>Revenue<\/td>\n<td>$<\/td>\n<td>2,663.4<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>2,320.7<\/td>\n<td><\/td>\n<td><\/td>\n<td>15<\/td>\n<td>%<\/td>\n<td><\/td>\n<td>15<\/td>\n<td>%<\/td>\n<\/tr>\n<tr>\n<td>Gross margin\u00a0<sup><em>(B)<\/em><\/sup><\/td>\n<td><\/td>\n<td>56.4<\/td>\n<td>%<\/td>\n<td><\/td>\n<td><\/td>\n<td>58.1<\/td>\n<td>%<\/td>\n<td><\/td>\n<td>(3<\/td>\n<td>)<\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Non-GAAP\u00a0gross margin\u00a0<sup><em>(B)<\/em><\/sup><\/td>\n<td><\/td>\n<td>57.6<\/td>\n<td>%<\/td>\n<td><\/td>\n<td><\/td>\n<td>59.8<\/td>\n<td>%<\/td>\n<td><\/td>\n<td>(4<\/td>\n<td>)<\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Selling, general, and administrative expenses<\/td>\n<td><\/td>\n<td>544.5<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>488.9<\/td>\n<td><\/td>\n<td><\/td>\n<td>11<\/td>\n<td><\/td>\n<td><\/td>\n<td>13<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Research and development expenses<\/td>\n<td><\/td>\n<td>189.3<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>165.4<\/td>\n<td><\/td>\n<td><\/td>\n<td>14<\/td>\n<td><\/td>\n<td><\/td>\n<td>15<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Income from operations<\/td>\n<td><\/td>\n<td>744.9<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>662.0<\/td>\n<td><\/td>\n<td><\/td>\n<td>13<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Non-GAAP\u00a0income from operations\u00a0<sup><em>(B)<\/em><\/sup><\/td>\n<td><\/td>\n<td>801.3<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>733.4<\/td>\n<td><\/td>\n<td><\/td>\n<td>9<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Net income<\/td>\n<td><\/td>\n<td>584.4<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>279.4<\/td>\n<td><\/td>\n<td><\/td>\n<td>109<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Non-GAAP\u00a0net income\u00a0<sup><em>(B)<\/em><\/sup><\/td>\n<td><\/td>\n<td>631.5<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>582.2<\/td>\n<td><\/td>\n<td><\/td>\n<td>8<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Diluted earnings per share<\/td>\n<td>$<\/td>\n<td>3.97<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1.91<\/td>\n<td><\/td>\n<td><\/td>\n<td>108<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Non-GAAP\u00a0diluted earnings per share\u00a0<sup><em>(B)<\/em><\/sup><\/td>\n<td>$<\/td>\n<td>4.30<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>3.98<\/td>\n<td><\/td>\n<td><\/td>\n<td>8<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>(A)\u00a0\u00a0\u00a0\u00a0\u00a0In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a \u201cconstant currency\u201d basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.<\/p>\n<p>(B)\u00a0\u00a0\u00a0\u00a0\u00a0See the reconciliation of\u00a0non-GAAP\u00a0financial measures in the table at the end of the press release.<\/p>\n<p><strong><em>Discussion of Third Quarter Results<\/em><\/strong><br \/>\n<em>All comparisons are to the prior year period unless otherwise noted<\/em><\/p>\n<ul type=\"disc\">\n<li>Revenue grew by 14\u00a0percent on a constant currency basis, driven by increased demand for our sleep and respiratory care devices and increased demand following a recent product recall by one of our competitors.\n<ul type=\"circle\">\n<li>Revenue in the U.S., Canada, and Latin America, excluding software-as-a-service, grew by 18 percent, primarily due to the factors discussed above and recovery of core sleep patient flow that was previously impacted by\u00a0COVID-19.<\/li>\n<li>Revenue in Europe, Asia, and other markets grew by 11\u00a0percent on a constant currency basis, primarily due to the factors discussed above.<\/li>\n<li>Software-as-a-service\u00a0revenue increased by 8\u00a0percent, due to continued growth in our Durable Medical Equipment category and stabilizing patient flow in\u00a0out-of-hospital\u00a0care settings.<\/li>\n<\/ul>\n<\/li>\n<li>Gross margin decreased by 140 basis points and\u00a0non-GAAP\u00a0gross margin decreased by 150 basis points, mainly due to higher freight and manufacturing costs, partially offset by favorable product mix changes and increase in average selling prices.<\/li>\n<li>Selling, general, and administrative expenses increased by 17\u00a0percent on a constant currency basis. SG&amp;A expenses increased to 21.1\u00a0percent of revenue in the quarter, compared with 20.9\u00a0percent in the same period of the prior year. These changes in SG&amp;A expenses were mainly due to increases in employee-related expenses.<\/li>\n<li>Income from operations increased by 5\u00a0percent and\u00a0non-GAAP\u00a0income from operations increased by 5 percent.<\/li>\n<li>Net income for the quarter was $179.0 million and diluted earnings per share was $1.22.\u00a0Non-GAAP\u00a0net income grew by 2\u00a0percent and\u00a0non-GAAP\u00a0diluted earnings per share grew by 2\u00a0percent, predominantly attributable to strong sales, partially offset by higher operating expenses.<\/li>\n<li>Operating cash flow for the quarter was $117.4 million, compared to net income in the current quarter of $179.0 million and\u00a0non-GAAP\u00a0net income of $193.3 million. During the quarter we paid $61.4 million in dividends.<\/li>\n<\/ul>\n<p><strong><em>Other Business and Operational Highlights<\/em><\/strong><\/p>\n<ul type=\"disc\">\n<li>Announced appointment of Urvashi Tyagi as new Chief Technology Officer and Bobby Ghoshal transitions to be President of ResMed\u2019s\u00a0software-as-a-service business segment full-time. Tyagi leads ResMed\u2019s digital health technology team, driving innovation and adoption of world-leading cloud-based digital health platforms and investments in emerging technologies.<\/li>\n<li>Published 2022 Global Sleep Surveys as part of National Sleep Awareness Week (March 13-19) and World Sleep Day (March 18). The surveys, conducted in the first quarter of the calendar year, asked nearly 25,000 respondents in 12 countries what\u2019s keeping them up at night; the results aim to build awareness of the critical role good sleep plays in physical and mental health.<\/li>\n<\/ul>\n<p><strong><em>Dividend program<\/em><\/strong><br \/>\nThe ResMed board of directors today declared a quarterly cash dividend of $0.42 per share. The dividend will have a record date of May\u00a012, 2022, payable on June\u00a016, 2022. The dividend will be paid in U.S. currency to holders of ResMed\u2019s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (\u201cCDIs\u201d) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The\u00a0ex-dividend\u00a0date will be May\u00a011, 2022, for common stockholders and for CDI holders. ResMed has received a waiver from the ASX\u2019s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from May\u00a011, 2022, through May\u00a012, 2022, inclusive.<\/p>\n<p><strong><em>Webcast details<\/em><\/strong><br \/>\nResMed will discuss its third-quarter fiscal year 2022 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed\u2019s Investor Relations website at\u00a0<u><a href=\"https:\/\/www.google.com\/url?q=http:\/\/investor.resmed.com&amp;source=gmail-html&amp;ust=1651297750446000&amp;usg=AOvVaw3v3sgccE0nErmG59KOKHF0\"  rel=\"noreferrer\">investor.resmed.com<\/a><\/u>. Please go to this section of the website and click on the icon for the \u201cQ3 2022 Earnings Webcast\u201d to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately two hours after the webcast by dialing +1\u00a0877-660-6853\u00a0(U.S.) or +1\u00a0201-612-7415\u00a0(outside U.S.) and entering the passcode 13727876. The telephone replay will be available until May 12, 2022.<\/p>\n<p><strong><em>About ResMed<\/em><\/strong><br \/>\nAt ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive\u00a0out-of-hospital\u00a0<wbr \/>software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries.\u00a0To learn more, visit\u00a0<u>ResMed.com<\/u>\u00a0and follow @ResMed.<\/p>\n<p><strong><em>Safe harbor statement<\/em><\/strong><br \/>\nStatements contained in this release that are not historical facts are \u201cforward-looking\u201d statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements \u2013 including statements regarding ResMed\u2019s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, litigation, and tax outlook \u2013 are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed\u2019s periodic reports on file with the U.S. Securities\u00a0&amp; Exchange Commission. ResMed does not undertake to update its forward-looking statements.<\/p>\n<p><strong>Condensed Consolidated Statements of Operations<\/strong><br \/>\n<em>(Unaudited; $ in thousands, except for per share amounts)<\/em><\/p>\n<div style=\"overflow-x: auto;\">\n<table>\n<tbody>\n<tr>\n<td><\/td>\n<td colspan=\"7\">Three Months Ended<\/td>\n<td><\/td>\n<td colspan=\"7\">Nine Months Ended<\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td colspan=\"3\">March 31,<br \/>\n2022<\/td>\n<td><\/td>\n<td colspan=\"3\">March 31,<br \/>\n2021<\/td>\n<td><\/td>\n<td colspan=\"3\">March 31,<br \/>\n2022<\/td>\n<td><\/td>\n<td colspan=\"3\">March 31,<br \/>\n2021<\/td>\n<\/tr>\n<tr>\n<td>Net revenue<\/td>\n<td>$<\/td>\n<td>864,500<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>768,767<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>2,663,390<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>2,320,722<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Cost of sales<\/td>\n<td><\/td>\n<td>362,321<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>310,585<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>1,128,314<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>933,021<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Amortization of acquired intangibles\u00a0<sup><em>(1)<\/em><\/sup><\/td>\n<td><\/td>\n<td>10,982<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>10,924<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>33,271<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>34,066<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Restructuring\u2014cost of sales\u00a0<sup><em>(1)<\/em><\/sup><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>5,232<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Total cost of sales<\/td>\n<td>$<\/td>\n<td>373,303<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>321,509<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1,161,585<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>972,319<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Gross profit<\/td>\n<td>$<\/td>\n<td>491,197<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>447,258<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1,501,805<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1,348,403<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Selling, general, and administrative<\/td>\n<td><\/td>\n<td>182,401<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>160,446<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>544,483<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>488,904<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Research and development<\/td>\n<td><\/td>\n<td>66,801<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>55,941<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>189,258<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>165,409<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Amortization of acquired intangibles\u00a0<sup><em>(1)<\/em><\/sup><\/td>\n<td><\/td>\n<td>7,730<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>7,445<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>23,175<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>23,377<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Restructuring\u2014operating expenses\u00a0<sup><em>(1)<\/em><\/sup><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>8,673<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Total operating expenses<\/td>\n<td>$<\/td>\n<td>256,932<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>223,832<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>756,916<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>686,363<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Income from operations<\/td>\n<td><\/td>\n<td>234,265<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>223,426<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>744,889<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>662,040<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Other income (expenses), net:<\/td>\n<td colspan=\"3\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<\/tr>\n<tr>\n<td>Interest income (expense), net<\/td>\n<td>$<\/td>\n<td>(5,462<\/td>\n<td>)<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>(5,823<\/td>\n<td>)<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>(16,770<\/td>\n<td>)<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>(18,341<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Loss attributable to equity method investments<\/td>\n<td><\/td>\n<td>(2,627<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(4,969<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(5,927<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(9,895<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Gain (loss) on equity investments<\/td>\n<td><\/td>\n<td>(1,735<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>4,666<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>(527<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>9,442<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Other, net<\/td>\n<td><\/td>\n<td>1,878<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>705<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>729<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>1,205<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Total other income (expenses), net<\/td>\n<td><\/td>\n<td>(7,946<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(5,421<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(22,495<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(17,589<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Income before income taxes<\/td>\n<td>$<\/td>\n<td>226,319<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>218,005<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>722,394<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>644,451<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Income taxes<\/td>\n<td><\/td>\n<td>47,307<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>296,486<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>138,018<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>365,046<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Net income (loss)<\/td>\n<td>$<\/td>\n<td>179,012<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>(78,481<\/td>\n<td>)<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>584,376<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>279,405<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Basic earnings per share<\/td>\n<td>$<\/td>\n<td>1.22<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>(0.54<\/td>\n<td>)<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>4.00<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1.92<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Diluted earnings per share<\/td>\n<td>$<\/td>\n<td>1.22<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>(0.54<\/td>\n<td>)<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>3.97<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1.91<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Non-GAAP\u00a0diluted earnings per share\u00a0<sup><em>(1)<\/em><\/sup><\/td>\n<td>$<\/td>\n<td>1.32<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1.30<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>4.30<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>3.98<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Basic shares outstanding<\/td>\n<td><\/td>\n<td>146,240<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>145,513<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>145,969<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>145,217<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Diluted shares outstanding<\/td>\n<td><\/td>\n<td>146,962<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>145,513<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>147,034<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>146,394<\/td>\n<td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>(1)\u00a0\u00a0\u00a0\u00a0See the reconciliation of\u00a0non-GAAP\u00a0financial measures in the table at the end of the press release.<\/p>\n<p><strong>Condensed Consolidated Balance Sheets<\/strong><br \/>\n<em>(Unaudited; $ in thousands)<\/em><\/p>\n<table>\n<tbody>\n<tr>\n<td><\/td>\n<td colspan=\"3\">March 31,<br \/>\n2022<\/td>\n<td><\/td>\n<td colspan=\"3\">June 30,<br \/>\n2021<\/td>\n<\/tr>\n<tr>\n<td><strong>ASSETS<\/strong><\/td>\n<td colspan=\"3\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<\/tr>\n<tr>\n<td>Current assets:<\/td>\n<td colspan=\"3\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<\/tr>\n<tr>\n<td>Cash and cash equivalents<\/td>\n<td>$<\/td>\n<td>201,769<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>295,278<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Accounts receivable, net<\/td>\n<td><\/td>\n<td>508,580<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>614,292<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Inventories<\/td>\n<td><\/td>\n<td>664,943<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>457,033<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Prepayments and other current assets<\/td>\n<td><\/td>\n<td>329,008<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>208,154<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Total current assets<\/td>\n<td>$<\/td>\n<td>1,704,300<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1,574,757<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Non-current\u00a0assets:<\/td>\n<td colspan=\"3\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<\/tr>\n<tr>\n<td>Property, plant, and equipment, net<\/td>\n<td>$<\/td>\n<td>513,250<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>463,490<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Operating lease\u00a0right-of-use\u00a0assets<\/td>\n<td><\/td>\n<td>141,173<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>128,575<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Goodwill and other intangibles, net<\/td>\n<td><\/td>\n<td>2,302,301<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>2,320,483<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Deferred income taxes and other\u00a0non-current\u00a0assets<\/td>\n<td><\/td>\n<td>244,240<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>240,820<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Total\u00a0non-current\u00a0assets<\/td>\n<td>$<\/td>\n<td>3,200,964<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>3,153,368<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Total assets<\/td>\n<td>$<\/td>\n<td>4,905,264<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>4,728,125<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td><strong>LIABILITIES AND STOCKHOLDERS\u2019 EQUITY:<\/strong><\/td>\n<td colspan=\"3\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<\/tr>\n<tr>\n<td>Current liabilities:<\/td>\n<td colspan=\"3\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<\/tr>\n<tr>\n<td>Accounts payable<\/td>\n<td>$<\/td>\n<td>149,797<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>138,008<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Accrued expenses<\/td>\n<td><\/td>\n<td>326,276<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>320,599<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Operating lease liabilities, current<\/td>\n<td><\/td>\n<td>24,130<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>23,585<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Deferred revenue<\/td>\n<td><\/td>\n<td>112,449<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>109,611<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Income taxes payable<\/td>\n<td><\/td>\n<td>42,646<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>307,963<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Short-term debt<\/td>\n<td><\/td>\n<td>11,967<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>12,000<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Total current liabilities<\/td>\n<td>$<\/td>\n<td>667,265<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>911,766<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Non-current\u00a0liabilities:<\/td>\n<td colspan=\"3\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<\/tr>\n<tr>\n<td>Deferred revenue<\/td>\n<td>$<\/td>\n<td>94,094<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>91,496<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Deferred income taxes<\/td>\n<td><\/td>\n<td>10,711<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>11,319<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Operating lease liabilities,\u00a0non-current<\/td>\n<td><\/td>\n<td>127,254<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>114,779<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Other long-term liabilities<\/td>\n<td><\/td>\n<td>5,103<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>6,802<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Long-term debt<\/td>\n<td><\/td>\n<td>668,735<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>643,351<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Long-term income taxes payable<\/td>\n<td><\/td>\n<td>53,298<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>62,933<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Total\u00a0non-current\u00a0liabilities<\/td>\n<td>$<\/td>\n<td>959,195<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>930,680<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Total liabilities<\/td>\n<td>$<\/td>\n<td>1,626,460<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1,842,446<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td><strong>STOCKHOLDERS\u2019 EQUITY:<\/strong><\/td>\n<td colspan=\"3\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<\/tr>\n<tr>\n<td>Common stock<\/td>\n<td>$<\/td>\n<td>585<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>583<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Additional\u00a0paid-in\u00a0capital<\/td>\n<td><\/td>\n<td>1,645,453<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>1,622,199<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Retained earnings<\/td>\n<td><\/td>\n<td>3,480,163<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>3,079,640<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Treasury stock<\/td>\n<td><\/td>\n<td>(1,623,256<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(1,623,256<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Accumulated other comprehensive income<\/td>\n<td><\/td>\n<td>(224,141<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(193,487<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Total stockholders\u2019 equity<\/td>\n<td>$<\/td>\n<td>3,278,804<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>2,885,679<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Total liabilities and stockholders\u2019 equity<\/td>\n<td>$<\/td>\n<td>4,905,264<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>4,728,125<\/td>\n<td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Condensed Consolidated Statements of Cash Flows<\/strong><br \/>\n<em>(Unaudited; $ in thousands)<\/em><\/p>\n<table>\n<tbody>\n<tr>\n<td><\/td>\n<td colspan=\"7\">Nine months ended<\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td colspan=\"3\">March 31,<br \/>\n2022<\/td>\n<td><\/td>\n<td colspan=\"3\">March 31,<br \/>\n2021<\/td>\n<\/tr>\n<tr>\n<td><strong>Cash flows from operating activities:<\/strong><\/td>\n<td colspan=\"3\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<\/tr>\n<tr>\n<td>Net income<\/td>\n<td>$<\/td>\n<td>584,376<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>279,405<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Adjustment to reconcile net income to cash provided by operating activities:<\/td>\n<td colspan=\"3\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<\/tr>\n<tr>\n<td>Depreciation and amortization<\/td>\n<td><\/td>\n<td>122,198<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>120,034<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Amortization of\u00a0right-of-use\u00a0assets<\/td>\n<td><\/td>\n<td>26,636<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>25,805<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Stock-based compensation costs<\/td>\n<td><\/td>\n<td>49,265<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>47,032<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Loss attributable to equity method investments<\/td>\n<td><\/td>\n<td>5,927<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>9,895<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>(Gain) loss on equity investment<\/td>\n<td><\/td>\n<td>527<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>(9,442<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Restructuring expenses<\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>8,673<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Changes in operating assets and liabilities:<\/td>\n<td colspan=\"3\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<\/tr>\n<tr>\n<td>Accounts receivable, net<\/td>\n<td><\/td>\n<td>98,158<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>(39,899<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Inventories, net<\/td>\n<td><\/td>\n<td>(209,476<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(48,393<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Prepaid expenses, net deferred income taxes and other current assets<\/td>\n<td><\/td>\n<td>(127,977<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(41,036<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Accounts payable, accrued expenses, income taxes payable and other<\/td>\n<td><\/td>\n<td>(277,973<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>158,119<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Net cash (used in) \/ provided by operating activities<\/td>\n<td>$<\/td>\n<td>271,661<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>510,193<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td><strong>Cash flows from investing activities:<\/strong><\/td>\n<td colspan=\"3\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<\/tr>\n<tr>\n<td>Purchases of property, plant, and equipment<\/td>\n<td><\/td>\n<td>(106,192<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(74,805<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Patent registration and acquisition costs<\/td>\n<td><\/td>\n<td>(17,449<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(11,149<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Business acquisitions, net of cash acquired<\/td>\n<td><\/td>\n<td>(35,915<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(30,704<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Purchases of investments<\/td>\n<td><\/td>\n<td>(16,614<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(20,038<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Proceeds from sale of investment<\/td>\n<td><\/td>\n<td>6,802<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>(Payments) \/ proceeds on maturity of foreign currency contracts<\/td>\n<td><\/td>\n<td>(5,309<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>26,306<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Net cash used in investing activities<\/td>\n<td>$<\/td>\n<td>(174,677<\/td>\n<td>)<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>(110,390<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td><strong>Cash flows from financing activities:<\/strong><\/td>\n<td colspan=\"3\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<\/tr>\n<tr>\n<td>Proceeds from issuance of common stock, net<\/td>\n<td><\/td>\n<td>26,269<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>18,759<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Taxes paid related to net share settlement of equity awards<\/td>\n<td><\/td>\n<td>(52,278<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(49,938<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Payments of business combination contingent consideration<\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>(3,500<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Proceeds from borrowings, net of borrowing costs<\/td>\n<td><\/td>\n<td>160,000<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>90,000<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Repayment of borrowings<\/td>\n<td><\/td>\n<td>(136,000<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(536,000<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Dividends paid<\/td>\n<td><\/td>\n<td>(183,853<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(169,917<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Net cash (used in) \/ provided by financing activities<\/td>\n<td>$<\/td>\n<td>(185,862<\/td>\n<td>)<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>(650,596<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Effect of exchange rate changes on cash<\/td>\n<td>$<\/td>\n<td>(4,631<\/td>\n<td>)<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>18,272<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Net increase \/ (decrease) in cash and cash equivalents<\/td>\n<td><\/td>\n<td>(93,509<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(232,521<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Cash and cash equivalents at beginning of period<\/td>\n<td><\/td>\n<td>295,278<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>463,156<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td><strong>Cash and cash equivalents at end of period<\/strong><\/td>\n<td>$<\/td>\n<td>201,769<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>230,635<\/td>\n<td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Reconciliation of\u00a0Non-GAAP\u00a0Financial Measures<\/strong><br \/>\n<em>(Unaudited; $ in thousands, except for per share amounts)<\/em><\/p>\n<p>The measures\u00a0\u201cnon-GAAP\u00a0gross profit\u201d and\u00a0\u201cnon-GAAP\u00a0gross margin\u201d exclude amortization expense from acquired intangibles related to cost of sales and are reconciled below:<\/p>\n<table>\n<tbody>\n<tr>\n<td><\/td>\n<td colspan=\"7\">Three Months Ended<\/td>\n<td><\/td>\n<td colspan=\"7\">Nine Months Ended<\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td colspan=\"3\">March 31, 2022<\/td>\n<td><\/td>\n<td colspan=\"3\">March 31, 2021<\/td>\n<td><\/td>\n<td colspan=\"3\">March 31, 2022<\/td>\n<td><\/td>\n<td colspan=\"3\">March 31, 2021<\/td>\n<\/tr>\n<tr>\n<td>Revenue<\/td>\n<td>$<\/td>\n<td>864,500<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>768,767<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>2,663,390<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>2,320,722<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>GAAP Cost of sales<\/td>\n<td>$<\/td>\n<td>373,303<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>321,509<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1,161,585<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>972,319<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td><em>Less:<\/em>\u00a0Amortization of acquired intangibles\u00a0<sup><em>(A)<\/em><\/sup><\/td>\n<td><\/td>\n<td>(10,982<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(10,924<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(33,271<\/td>\n<td>)<\/td>\n<td><\/td>\n<td><\/td>\n<td>(34,066<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td><em>Less:<\/em>\u00a0Restructuring\u2014cost of sales\u00a0<sup><em>(A)<\/em><\/sup><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>(5,232<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Non-GAAP\u00a0cost of sales<\/td>\n<td>$<\/td>\n<td>362,321<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>310,585<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1,128,314<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>933,021<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>GAAP gross profit<\/td>\n<td>$<\/td>\n<td>491,197<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>447,258<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1,501,805<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1,348,403<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>GAAP gross margin<\/td>\n<td><\/td>\n<td>56.8<\/td>\n<td>%<\/td>\n<td><\/td>\n<td><\/td>\n<td>58.2<\/td>\n<td>%<\/td>\n<td><\/td>\n<td><\/td>\n<td>56.4<\/td>\n<td>%<\/td>\n<td><\/td>\n<td><\/td>\n<td>58.1<\/td>\n<td>%<\/td>\n<\/tr>\n<tr>\n<td>Non-GAAP\u00a0gross profit<\/td>\n<td>$<\/td>\n<td>502,179<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>458,182<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1,535,076<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1,387,701<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Non-GAAP\u00a0gross margin<\/td>\n<td><\/td>\n<td>58.1<\/td>\n<td>%<\/td>\n<td><\/td>\n<td><\/td>\n<td>59.6<\/td>\n<td>%<\/td>\n<td><\/td>\n<td><\/td>\n<td>57.6<\/td>\n<td>%<\/td>\n<td><\/td>\n<td><\/td>\n<td>59.8<\/td>\n<td>%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The measure\u00a0\u201cnon-GAAP\u00a0income from operations\u201d is reconciled with GAAP income from operations below:<\/p>\n<table>\n<tbody>\n<tr>\n<td><\/td>\n<td colspan=\"5\">Three Months Ended<\/td>\n<td><\/td>\n<td colspan=\"5\">Nine Months Ended<\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td colspan=\"2\">March 31,<br \/>\n2022<\/td>\n<td><\/td>\n<td colspan=\"2\">March 31,<br \/>\n2021<\/td>\n<td><\/td>\n<td colspan=\"2\">March 31,<br \/>\n2022<\/td>\n<td><\/td>\n<td colspan=\"2\">March 31,<br \/>\n2021<\/td>\n<\/tr>\n<tr>\n<td>GAAP income from operations<\/td>\n<td>$<\/td>\n<td>234,265<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>223,426<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>744,889<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>662,040<\/td>\n<\/tr>\n<tr>\n<td>Amortization of acquired intangibles\u2014cost of sales\u00a0<sup><em>(A)<\/em><\/sup><\/td>\n<td><\/td>\n<td>10,982<\/td>\n<td><\/td>\n<td><\/td>\n<td>10,924<\/td>\n<td><\/td>\n<td><\/td>\n<td>33,271<\/td>\n<td><\/td>\n<td><\/td>\n<td>34,066<\/td>\n<\/tr>\n<tr>\n<td>Amortization of acquired intangibles\u2014operating expenses\u00a0<sup><em>(A<\/em><\/sup><sup>)<\/sup><\/td>\n<td><\/td>\n<td>7,730<\/td>\n<td><\/td>\n<td><\/td>\n<td>7,445<\/td>\n<td><\/td>\n<td><\/td>\n<td>23,175<\/td>\n<td><\/td>\n<td><\/td>\n<td>23,377<\/td>\n<\/tr>\n<tr>\n<td>Restructuring\u2014cost of sales\u00a0<sup><em>(A)<\/em><\/sup><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td>5,232<\/td>\n<\/tr>\n<tr>\n<td>Restructuring\u2014operating expenses\u00a0<sup><em>(A)<\/em><\/sup><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td>8,673<\/td>\n<\/tr>\n<tr>\n<td>Non-GAAP\u00a0income from operations<\/td>\n<td>$<\/td>\n<td>252,977<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>241,795<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>801,335<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>733,388<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Reconciliation of\u00a0Non-GAAP\u00a0Financial Measures<\/strong><br \/>\n<em>(Unaudited; $ in thousands, except for per share amounts)<\/em><\/p>\n<p>The measures\u00a0\u201cnon-GAAP\u00a0net income\u201d and\u00a0\u201cnon-GAAP\u00a0diluted earnings per share\u201d are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:<\/p>\n<table>\n<tbody>\n<tr>\n<td><\/td>\n<td colspan=\"6\">Three Months Ended<\/td>\n<td><\/td>\n<td colspan=\"6\">Nine Months Ended<\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td colspan=\"2\">March 31,<br \/>\n2022<\/td>\n<td><\/td>\n<td colspan=\"3\">March 31,<br \/>\n2021<\/td>\n<td><\/td>\n<td colspan=\"2\">March 31,<br \/>\n2022<\/td>\n<td><\/td>\n<td colspan=\"3\">March 31,<br \/>\n2021<\/td>\n<\/tr>\n<tr>\n<td>GAAP net income (loss)<\/td>\n<td>$<\/td>\n<td>179,012<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>(78,481<\/td>\n<td>)<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>584,376<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>279,405<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Amortization of acquired intangibles\u2014cost of sales, net of tax<sup><em>(A)<\/em><\/sup><\/td>\n<td><\/td>\n<td>8,374<\/td>\n<td><\/td>\n<td><\/td>\n<td>8,395<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>25,373<\/td>\n<td><\/td>\n<td><\/td>\n<td>26,136<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Amortization of acquired intangibles\u2014operating expenses, net of tax<sup><em>(A)<\/em><\/sup><\/td>\n<td><\/td>\n<td>5,894<\/td>\n<td><\/td>\n<td><\/td>\n<td>5,721<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>17,673<\/td>\n<td><\/td>\n<td><\/td>\n<td>17,936<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Reserve for disputed tax position<sup><em>(A)<\/em><\/sup><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td>254,776<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>4,111<\/td>\n<td><\/td>\n<td><\/td>\n<td>254,776<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Restructuring\u2014cost of sales, net of tax<sup><em>(A)<\/em><\/sup><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td>4,663<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Restructuring\u2014operating expenses, net of tax<sup><em>(A)<\/em><\/sup><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td>7,730<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>(Gain) loss on equity investments<sup><em>(A)<\/em><\/sup><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td>(8,476<\/td>\n<td>)<\/td>\n<\/tr>\n<tr>\n<td>Non-GAAP\u00a0net income<sup><em>(A)<\/em><\/sup><\/td>\n<td>$<\/td>\n<td>193,280<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>190,411<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>631,533<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>582,170<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>GAAP diluted shares outstanding<\/td>\n<td><\/td>\n<td>146,962<\/td>\n<td><\/td>\n<td><\/td>\n<td>145,513<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>147,034<\/td>\n<td><\/td>\n<td><\/td>\n<td>146,394<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Anti-dilutive shares excluded from GAAP<\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td>858<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<td><\/td>\n<td>\u2014<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Non-GAAP diluted shares outstanding<\/td>\n<td><\/td>\n<td>146,962<\/td>\n<td><\/td>\n<td><\/td>\n<td>146,371<\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td>147,034<\/td>\n<td><\/td>\n<td><\/td>\n<td>146,394<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>GAAP diluted earnings (loss) per share<\/td>\n<td>$<\/td>\n<td>1.22<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>(0.54<\/td>\n<td>)<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>3.97<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1.91<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Non-GAAP\u00a0diluted earnings per share<sup><em>(A)<\/em><\/sup><\/td>\n<td>$<\/td>\n<td>1.32<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1.30<\/td>\n<td><\/td>\n<td><\/td>\n<td>$<\/td>\n<td>4.30<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>3.98<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"3\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>(A)\u00a0\u00a0\u00a0\u00a0\u00a0ResMed adjusts for the impact of the amortization of acquired intangibles, reserve for disputed tax positions, restructuring expenses and the (gain) loss on equity investments from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.<\/p>\n<p>ResMed believes that\u00a0non-GAAP\u00a0diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses\u00a0non-GAAP\u00a0information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed\u2019s performance from core operations and provides consistent financial reporting. The use of\u00a0non-GAAP\u00a0measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all\u00a0non-GAAP\u00a0measures,\u00a0non-<wbr \/>GAAP\u00a0earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.<\/p>\n<p><strong>Revenue by Product and Region<\/strong><br \/>\n<em>(Unaudited; $ in millions, except for per share amounts)<\/em><\/p>\n<table>\n<tbody>\n<tr>\n<td><\/td>\n<td colspan=\"11\">Three Months Ended<\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td colspan=\"2\">March 31,<br \/>\n2022<\/td>\n<td><sup><em>(A)<\/em><\/sup><\/td>\n<td colspan=\"2\">March 31,<br \/>\n2021<\/td>\n<td><sup><em>(A)<\/em><\/sup><\/td>\n<td colspan=\"2\">%\u00a0Change<\/td>\n<td><\/td>\n<td colspan=\"2\">Constant<br \/>\nCurrency<sup><em>\u00a0(B)<\/em><\/sup><\/td>\n<\/tr>\n<tr>\n<td><strong>U.S., Canada, and Latin America<\/strong><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Devices<\/td>\n<td>$<\/td>\n<td>250.8<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>192.9<\/td>\n<td><\/td>\n<td>30<\/td>\n<td>%<\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Masks and other<\/td>\n<td><\/td>\n<td>224.7<\/td>\n<td><\/td>\n<td><\/td>\n<td>210.0<\/td>\n<td><\/td>\n<td>7<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Total Sleep and Respiratory Care<\/td>\n<td>$<\/td>\n<td>475.4<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>402.9<\/td>\n<td><\/td>\n<td>18<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Software as a Service<\/td>\n<td><\/td>\n<td>101.1<\/td>\n<td><\/td>\n<td><\/td>\n<td>93.8<\/td>\n<td><\/td>\n<td>8<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Total<\/td>\n<td>$<\/td>\n<td>576.6<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>496.7<\/td>\n<td><\/td>\n<td>16<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td><strong>Combined Europe, Asia, and other markets<\/strong><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Devices<\/td>\n<td>$<\/td>\n<td>182.3<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>172.8<\/td>\n<td><\/td>\n<td>5<\/td>\n<td>%<\/td>\n<td><\/td>\n<td>10<\/td>\n<td>%<\/td>\n<\/tr>\n<tr>\n<td>Masks and other<\/td>\n<td><\/td>\n<td>105.6<\/td>\n<td><\/td>\n<td><\/td>\n<td>99.2<\/td>\n<td><\/td>\n<td>6<\/td>\n<td><\/td>\n<td><\/td>\n<td>13<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Total Sleep and Respiratory Care<\/td>\n<td>$<\/td>\n<td>287.9<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>272.1<\/td>\n<td><\/td>\n<td>6<\/td>\n<td><\/td>\n<td><\/td>\n<td>11<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td><strong>Global revenue<\/strong><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Devices<\/td>\n<td>$<\/td>\n<td>433.1<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>365.7<\/td>\n<td><\/td>\n<td>18<\/td>\n<td>%<\/td>\n<td><\/td>\n<td>21<\/td>\n<td>%<\/td>\n<\/tr>\n<tr>\n<td>Masks and other<\/td>\n<td><\/td>\n<td>330.3<\/td>\n<td><\/td>\n<td><\/td>\n<td>309.2<\/td>\n<td><\/td>\n<td>7<\/td>\n<td><\/td>\n<td><\/td>\n<td>9<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Total Sleep and Respiratory Care<\/td>\n<td>$<\/td>\n<td>763.4<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>674.9<\/td>\n<td><\/td>\n<td>13<\/td>\n<td><\/td>\n<td><\/td>\n<td>15<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Software as a Service<\/td>\n<td><\/td>\n<td>101.1<\/td>\n<td><\/td>\n<td><\/td>\n<td>93.8<\/td>\n<td><\/td>\n<td>8<\/td>\n<td><\/td>\n<td><\/td>\n<td>8<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Total<\/td>\n<td>$<\/td>\n<td>864.5<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>768.8<\/td>\n<td><\/td>\n<td>12<\/td>\n<td><\/td>\n<td><\/td>\n<td>14<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<table>\n<tbody>\n<tr>\n<td><\/td>\n<td colspan=\"11\">Nine Months Ended<\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td colspan=\"2\">March 31,<br \/>\n2022<\/td>\n<td><sup><em>(A)<\/em><\/sup><\/td>\n<td colspan=\"2\">March 31,<br \/>\n2021<\/td>\n<td><sup><em>(A)<\/em><\/sup><\/td>\n<td colspan=\"2\">%<br \/>\nChange<\/td>\n<td><\/td>\n<td colspan=\"2\">Constant<br \/>\nCurrency\u00a0<sup><em>(B)<\/em><\/sup><\/td>\n<\/tr>\n<tr>\n<td><strong>U.S., Canada, and Latin America<\/strong><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Devices<\/td>\n<td>$<\/td>\n<td>771.5<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>595.3<\/td>\n<td><\/td>\n<td>30<\/td>\n<td>%<\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Masks and other<\/td>\n<td><\/td>\n<td>681.8<\/td>\n<td><\/td>\n<td><\/td>\n<td>637.5<\/td>\n<td><\/td>\n<td>7<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Total Sleep and Respiratory Care<\/td>\n<td>$<\/td>\n<td>1,453.3<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1,232.8<\/td>\n<td><\/td>\n<td>18<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Software as a Service<\/td>\n<td><\/td>\n<td>297.7<\/td>\n<td><\/td>\n<td><\/td>\n<td>277.8<\/td>\n<td><\/td>\n<td>7<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Total<\/td>\n<td>$<\/td>\n<td>1,751.0<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1,510.6<\/td>\n<td><\/td>\n<td>16<\/td>\n<td><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td><strong>Combined Europe, Asia, and other markets<\/strong><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Devices<\/td>\n<td>$<\/td>\n<td>608.3<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>536.9<\/td>\n<td><\/td>\n<td>13<\/td>\n<td>%<\/td>\n<td><\/td>\n<td>15<\/td>\n<td>%<\/td>\n<\/tr>\n<tr>\n<td>Masks and other<\/td>\n<td><\/td>\n<td>304.2<\/td>\n<td><\/td>\n<td><\/td>\n<td>273.3<\/td>\n<td><\/td>\n<td>11<\/td>\n<td><\/td>\n<td><\/td>\n<td>14<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Total Sleep and Respiratory Care<\/td>\n<td>$<\/td>\n<td>912.4<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>810.1<\/td>\n<td><\/td>\n<td>13<\/td>\n<td><\/td>\n<td><\/td>\n<td>15<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td><strong>Global revenue<\/strong><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<td><\/td>\n<td colspan=\"2\"><\/td>\n<\/tr>\n<tr>\n<td>Devices<\/td>\n<td>$<\/td>\n<td>1,379.7<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>1,132.1<\/td>\n<td><\/td>\n<td>22<\/td>\n<td>%<\/td>\n<td><\/td>\n<td>23<\/td>\n<td>%<\/td>\n<\/tr>\n<tr>\n<td>Masks and other<\/td>\n<td><\/td>\n<td>986.0<\/td>\n<td><\/td>\n<td><\/td>\n<td>910.8<\/td>\n<td><\/td>\n<td>8<\/td>\n<td><\/td>\n<td><\/td>\n<td>9<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Total Sleep and Respiratory Care<\/td>\n<td>$<\/td>\n<td>2,365.7<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>2,042.9<\/td>\n<td><\/td>\n<td>16<\/td>\n<td><\/td>\n<td><\/td>\n<td>16<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Software as a Service<\/td>\n<td><\/td>\n<td>297.7<\/td>\n<td><\/td>\n<td><\/td>\n<td>277.8<\/td>\n<td><\/td>\n<td>7<\/td>\n<td><\/td>\n<td><\/td>\n<td>7<\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Total<\/td>\n<td>$<\/td>\n<td>2,663.4<\/td>\n<td><\/td>\n<td>$<\/td>\n<td>2,320.7<\/td>\n<td><\/td>\n<td>15<\/td>\n<td><\/td>\n<td><\/td>\n<td>15<\/td>\n<td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>(A)\u00a0\u00a0\u00a0\u00a0Totals and subtotals may not add due to rounding.<\/p>\n<p>(B)\u00a0\u00a0\u00a0\u00a0In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a \u201cconstant currency basis,\u201d which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.<\/p>\n<table>\n<tbody>\n<tr>\n<td><strong>For investors<\/strong><\/td>\n<td><strong>For media<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Amy Wakeham<\/td>\n<td>Jayme Rubenstein<\/td>\n<\/tr>\n<tr>\n<td>+1\u00a0858-836-5000<\/td>\n<td>+1\u00a0858-836-6798<\/td>\n<\/tr>\n<tr>\n<td><u><a href=\"mailto:investorrelations@resmed.com\"  rel=\"noreferrer\">investorrelations@resmed.com<\/a><\/u><\/td>\n<td><u><a href=\"mailto:news@resmed.com\"  rel=\"noreferrer\">news@resmed.com<\/a><\/u><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Year-over-year revenue grows 12%, operating profit up 5%,\u00a0non-GAAP\u00a0operating profit up 5% Note: A webcast of ResMed\u2019s conference call will be available at 4:30 p.m. ET today at\u00a0http:\/\/investor.resmed.com SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) \u2014 ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March\u00a031, 2022. Third Quarter 2022 Highlights All [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022 - Taiwan Newswire<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022 - Taiwan Newswire\" \/>\n<meta property=\"og:description\" content=\"Year-over-year revenue grows 12%, operating profit up 5%,\u00a0non-GAAP\u00a0operating profit up 5% Note: A webcast of ResMed\u2019s conference call will be available at 4:30 p.m. ET today at\u00a0http:\/\/investor.resmed.com SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) \u2014 ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March\u00a031, 2022. Third Quarter 2022 Highlights All [\u2026]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Taiwan Newswire\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-29T05:50:41+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/taiwannewswire.com\/#\/schema\/person\/90e83744b6bae95cc57e0b9b64e42ae1\"},\"headline\":\"ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022\",\"datePublished\":\"2022-04-29T05:50:41+00:00\",\"dateModified\":\"2022-04-29T05:50:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/\"},\"wordCount\":2627,\"publisher\":{\"@id\":\"https:\/\/taiwannewswire.com\/#organization\"},\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/\",\"url\":\"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/\",\"name\":\"ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022 - Taiwan Newswire\",\"isPartOf\":{\"@id\":\"https:\/\/taiwannewswire.com\/#website\"},\"datePublished\":\"2022-04-29T05:50:41+00:00\",\"dateModified\":\"2022-04-29T05:50:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/taiwannewswire.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/taiwannewswire.com\/#website\",\"url\":\"https:\/\/taiwannewswire.com\/\",\"name\":\"Taiwan Newswire\",\"description\":\"Discover the World through News.\",\"publisher\":{\"@id\":\"https:\/\/taiwannewswire.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/taiwannewswire.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/taiwannewswire.com\/#organization\",\"name\":\"Taiwan Newswire\",\"url\":\"https:\/\/taiwannewswire.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/taiwannewswire.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/taiwannewswire.com\/wp-content\/uploads\/2020\/06\/logo-taiwan.png\",\"contentUrl\":\"https:\/\/taiwannewswire.com\/wp-content\/uploads\/2020\/06\/logo-taiwan.png\",\"width\":216,\"height\":84,\"caption\":\"Taiwan Newswire\"},\"image\":{\"@id\":\"https:\/\/taiwannewswire.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/taiwannewswire.com\/#\/schema\/person\/90e83744b6bae95cc57e0b9b64e42ae1\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/taiwannewswire.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/taiwannewswire.com\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022 - Taiwan Newswire","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/","og_locale":"en_US","og_type":"article","og_title":"ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022 - Taiwan Newswire","og_description":"Year-over-year revenue grows 12%, operating profit up 5%,\u00a0non-GAAP\u00a0operating profit up 5% Note: A webcast of ResMed\u2019s conference call will be available at 4:30 p.m. ET today at\u00a0http:\/\/investor.resmed.com SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) \u2014 ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March\u00a031, 2022. Third Quarter 2022 Highlights All [\u2026]","og_url":"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/","og_site_name":"Taiwan Newswire","article_published_time":"2022-04-29T05:50:41+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/#article","isPartOf":{"@id":"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/"},"author":{"name":"admin","@id":"https:\/\/taiwannewswire.com\/#\/schema\/person\/90e83744b6bae95cc57e0b9b64e42ae1"},"headline":"ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022","datePublished":"2022-04-29T05:50:41+00:00","dateModified":"2022-04-29T05:50:41+00:00","mainEntityOfPage":{"@id":"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/"},"wordCount":2627,"publisher":{"@id":"https:\/\/taiwannewswire.com\/#organization"},"articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/","url":"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/","name":"ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022 - Taiwan Newswire","isPartOf":{"@id":"https:\/\/taiwannewswire.com\/#website"},"datePublished":"2022-04-29T05:50:41+00:00","dateModified":"2022-04-29T05:50:41+00:00","breadcrumb":{"@id":"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/taiwannewswire.com\/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/taiwannewswire.com\/"},{"@type":"ListItem","position":2,"name":"ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022"}]},{"@type":"WebSite","@id":"https:\/\/taiwannewswire.com\/#website","url":"https:\/\/taiwannewswire.com\/","name":"Taiwan Newswire","description":"Discover the World through News.","publisher":{"@id":"https:\/\/taiwannewswire.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/taiwannewswire.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/taiwannewswire.com\/#organization","name":"Taiwan Newswire","url":"https:\/\/taiwannewswire.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/taiwannewswire.com\/#\/schema\/logo\/image\/","url":"https:\/\/taiwannewswire.com\/wp-content\/uploads\/2020\/06\/logo-taiwan.png","contentUrl":"https:\/\/taiwannewswire.com\/wp-content\/uploads\/2020\/06\/logo-taiwan.png","width":216,"height":84,"caption":"Taiwan Newswire"},"image":{"@id":"https:\/\/taiwannewswire.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/taiwannewswire.com\/#\/schema\/person\/90e83744b6bae95cc57e0b9b64e42ae1","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/taiwannewswire.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/taiwannewswire.com\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/taiwannewswire.com\/wp-json\/wp\/v2\/posts\/201522"}],"collection":[{"href":"https:\/\/taiwannewswire.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/taiwannewswire.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/taiwannewswire.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/taiwannewswire.com\/wp-json\/wp\/v2\/comments?post=201522"}],"version-history":[{"count":0,"href":"https:\/\/taiwannewswire.com\/wp-json\/wp\/v2\/posts\/201522\/revisions"}],"wp:attachment":[{"href":"https:\/\/taiwannewswire.com\/wp-json\/wp\/v2\/media?parent=201522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/taiwannewswire.com\/wp-json\/wp\/v2\/categories?post=201522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/taiwannewswire.com\/wp-json\/wp\/v2\/tags?post=201522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}